DIAdvisor

The DIAdvisor is a large scale- integrating project (IP) aiming at development of a prediction based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

The DIAdvisor does not depend on specific sensor technologies and technologies like standard strip sensing, minimally invasive continuous glucose sensors and non-invasive methods.

For safety reason, the DIAdvisor system will be able to self-assess the confidence of its proposed decisions. For safety reasons as well as for the sake of therapy improvements the system connects and provides information and trends to the Health Care Provider.

Glucose prediction is difficult and requires advanced science. This can be achieved only by a well-balanced group of eminent experts including academics, clinicians, user representatives and leading companies. This includes physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding.

The expected impact of DIAdvisor will be improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs. Moreover, the project will constitute a valuable opportunity for European companies to build up a special know-how leading products that profoundly and positively impacts the lives of millions with other indications than diabetes.

For further information, please visit:
http://www.diadvisor.eu/

Project co-ordinator:
Novo Nordisk A/S (Denmark)

Partners:

  • Novo Nordisk A/S (Denmark),
  • Johannes Kepler Universität Linz (Austria),
  • Lunds Universitet (Sweden),
  • Universita Degli Studi di Padova (Italy),
  • Centre Hospitalier Regional Universitaire de Montpellier (France),
  • Toumaz Technology Ltd (UK),
  • Sensor Technology and Devices Ltd (UK),
  • Ondalys SARL (France),
  • Romsoft SRL (Romania),
  • Institut Klinicke a Experimentalni Mediciny (Czech Republic),
  • RICAM, Österreichische Akademie der Wissenschaften (Austria),
  • Rambøll Danmark A/S (Denmark),
  • Federation Internationale du Diabete Region Europe (Belgium)

Timetable: from 03/2008 – to 02/2012

Total cost: € 9.284.061

EC funding: € 7.099.992

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Artificial Intelligence Solution Improve…

Clinical trials are a critical tool for getting new treatments to people who need them, but research shows that difficulty finding the right volunteer subjects can undermine the effectiveness of...

Cardio-Respiratory Synchronization may R…

Researchers from the School of Engineering at the University of Warwick have managed to expand the knowledge of the cardio-respiratory system after conducting an experiment measuring heart rate during fast-paced...

South West London Pathology Picks CliniS…

One of the first pathology networks in the country, set up to serve more than two million people in south west London, has signed a contract with CliniSys for a...

AI-based AI-Rad Companion Chest CT Softw…

AI-Rad Companion Chest CT(1), an intelligent software assistant for radiology, was recently awarded the CE mark, which means Siemens Healthineers can start marketing this artificial intelligence (AI)-based software as a...

Spot On for Healthcare Technology Startu…

10 - 12 October 2019, Berlin, Germany. XPOMET Medicinale brings together care providers, patients, and in general stakeholders from all health-related fields and geographic regions. The Festival of Future Medicine and...

Call for Tenders: Studies on eHealth, In…

The European Commission is launching a tender for two studies to survey and analyse progress on the digital transformation of the health and care in the EU, in particular with...

7th MEDICA MEDICINE + SPORTS CONFERENCE

18 - 21 November 2019, Düsseldorf, Germany. What lengths do top athletes go to in order to reach peak performances and which findings in the field of professional sports are relevant...

Carestream Health Completes Sale of Heal…

Carestream Healthhas completed the sale of the company's healthcare information solutions business to Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, in 26 of the 38...

How can We Successfully Converge the Hea…

Opinion Article by Erik Janssen, VP, Innovative Solutions, Neurology, UCB Pharma. The fourth industrial revolution is upon us and fundamentally changing the way we live, work and interact across all industries...

Isansys Named as Finalist for OBN's Most…

Isansys Lifecare is proud to announce it has been shortlisted in the Most Transformative Digital Healthcare Company category at the OBN Annual Awards 2019. The award recognises the significant uptake...